The Glucagon-Like Peptide-1 Receptor—or Not?
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1)-based diabetes therapy is increasingly used in the treatment of type 2 diabetes. Two GLP-1 analogs, liraglutide and exenatide, have been approved for clinical use and act as agonists of the GLP-1 receptor (GLP-1R), a member of the glucagon receptor family of G protein-coupled receptors (GPCRs) (1). Also, the clinical effect of Di-Peptidyl Peptidase-4 (DPP-4) inhibitors is at least partially resulting from an increased level of active GLP-1 (2). The unambiguous identification of GLP-1R-expressing cells in humans and animal species constitutes critically important knowledge for fully understanding the pharmacological effects of GLP-1R agonists, both those associated with the documented clinical benefits as well as any potential undesired effects of treatment. The GLP-1R was cloned in 1992 (3). Preceding that, the receptor was identified in numerous cell types and organs, most obviously the pancreatic β-cell but also in rat lung and brain by studies using either ligand binding or functional assays (4, 5). After the receptor was cloned, RT-PCR and in situ hybridization were used to report tissue distribution, and the receptor was located in the intestine, stomach, kidney, lungs, heart, and brain (6, 7). Later studies have used Western blotting and immunohistochemistry to identify the exact cellular localization of the receptor. Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9). Human GLP-1R expression has been mapped by in situ ligand binding across a wide range of both normal and tumor tissues (10). In this issue of Endocrinology, Panjwani et al. (11) reports new knowledge about the mechanism of action of GLP-1 analogs in atherosclerosis and hepatic steatosis and challenges some GLP-1R expression data in macrophages and hepatocytes that have previously been published. When Panjwani et al. (11) could not identify GLP-1R mRNA on macrophages or isolated hepatocytes despite previous reports of such localization, they did a careful Western blotting characterization of three commercially available polyclonal antibodies (PAbs) against the GLP-1R that are commonly used for Western blotting. They used mouse wild-type lung tissue that has a very high expression of GLP-1R as a positive control and lung tissue from GLP-1R−/− mice as a negative control. They also employed a very thorough procedure with immunoprecipitation in an attempt to increase the sensitivity of the analysis but found no GLP-1R-specific expression. The authors conclude that multiple commercially available GLP-1R antibodies do not detect authentic GLP-1R protein, even using optimally enhanced methods. This technical difficulty at first glance seems to have little bearing on aspects of GLP-1 biology unrelated to the scope of the article; however, on further consideration, it brings into focus a potentially serious problem with the validity of any GLP-1R expression data generated through the use of antibodies. Adding to the complexity, for some GLP-1R-containing organs, markedly different GLP-1R expression patterns have been reported between human and rodent species (10, 12). Rodent thyroid C-cells express much higher levels of GLP-1R than primates (10, 12), and there may be an important species difference, where the GLP-1R in the rodent thyroid is important for the high bone turnover in those species but less important in humans (13, 14). In the lung, the number of GLP-1R-expressing cells and the receptor density is much lower in humans than in rodent species (10), but the role and importance of lung GLP-1R is relatively unexplored. Three different histological techniques are available for mapping the identity of cells expressing a receptor like the GLP-1R. First, in situ hybridization is the method of choice for detecting mRNA in tissues; however, for a low-abundance target like the GLP-1R, only methods depending on the use of radioactively labeled probes will provide the required sensitivity, and unfortunately, the final autoradiography step severely limits the resolution of the output signal. A similar problem exists for in situ ligand binding (ISLB) with radioactively labeled ligand, although this method has been highly useful for detecting a functional GLP-1R in cell types that can be identified despite the limited resolution (12, 15). The third method, and the one most often employed to map GLP-1R localization by researchers in the field, is immunohistochemistry (IHC) with anti-GLP-1R antibodies. IHC offers the best resolution and allows unambiguous cell identification; however, for GPCRs, it is notoriously difficult, and a high focus on validation of antibodies and protocols is imperative. Further adding to the difficulty of generating reliable GPCR protein expression data, the normal physiological cell density of many GPCRs can be very low. In one issue of the journal Naunyn-Schmiedeberg’s Archives
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [39]
In the citing paper
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [11]
In the citing paper
“However, these studies were later refuted, as incompletely validated GLP-1 receptor antisera were used (81).”
From Safety of Semaglutide (2021) · cites this paper as [81]
Citations
Cites
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Using such techniques, the receptor has been identified in mouse cardiomyocytes and smooth muscle cells in the heart, and in porcine tubular cells in the kidney (8, 9).”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Self-citationTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 1×
“the intestine, stomach, kidney, lungs, heart, and brain (6, 7).”
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“Adding to the complexity, for some GLP-1R-containing organs, markedly different GLP-1R expression patterns have been reported between human and rodent species (10, 12).”
BackgroundInfluentialGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“A similar problem exists for in situ ligand binding (ISLB) with radioactively labeled ligand, although this method has been highly useful for detecting a functional GLP-1R in cell types that can be identified despite the limited resolution (12, 15).”
MethodCampos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 2×
“(11) reports new knowledge about the mechanism of action of GLP-1 analogs in atherosclerosis and hepatic steatosis and challenges some GLP-1R expression data in”
BackgroundThe Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
How reliable are G-protein-coupled receptor antibodies?
Michel, M. C., Wieland, T., & Tsujimoto, G. (2009) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-009-0395-y · Cited by 306
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“The majority of antisera used to localize mouse and human GLP1R expression do not in fact recognize the GLP-1R under commonly utilized experimental conditions (Panjwani et al., 2013; Pyke and Knudsen, 2013).”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Self-citationThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
“However, these studies were later refuted, as incompletely validated GLP-1 receptor antisera were used (81).”
ResultGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
“Similar problems with the sensitivity and specificity of GLP-1R antisera have been described by others (7).”
BackgroundMethodHeppner, K. M., Kirigiti, M., Secher, A., Paulsen, S. J., Buckingham, R., Pyke, C., Knudsen, L. B., Vrang, N., & Grove, K. L. (2015) · Endocrinology · doi:10.1210/en.2014-1675 · Cited by 196
Self-citationIncretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Iacobellis, G., & Villasante Fricke, A. C. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz042 · Cited by 168
Botfield, H. F., Uldall, M. S., Westgate, C. S. J., Mitchell, J. L., Hagen, S. M., Gonzalez, A. M., Hodson, D. J., Jensen, R. H., & Sinclair, A. J. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0972 · Cited by 163
“In any case, our studies are in keeping with others showing localization of the GLP-1R in monkey kidney and human GLP-1R transfected cells (20, 21).”
MethodResultAst, J., Arvaniti, A., Fine, N. H. F., Nasteska, D., Ashford, F. B., Stamataki, Z., Kőszegi, Z., Bacon, A., Jones, B. J., Lucey, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14309-w · Cited by 150
Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
Cameron-Vendrig, A., Adili, R., Siraj, M. A., Xu, X., Wang, Y., Lei, X., Afroze, T., Shikatani, E. A., El-Mounayri, O., Noyan, H., et al. (2016) · Diabetes · doi:10.2337/db15-1141 · Cited by 149
“Human Megakaryocytes and Platelets Express a Functional GLP-1R Given the variety of concerns with currently available GLP-1R antibodies (33), we began our studies by exploring the expression of GLP-1R at the mRNA level.”
BackgroundExendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., et al. (2014) · Diabetes · doi:10.2337/db13-1169 · Cited by 147
“Because the sensitivity and specificity of the available anti–GLP-1R antibodies are currently under discussion (28), the specificity of the anti–GLP-1R antibody used in this study was confirmed using GLP-1R–overexpressing COS-7 cells (Supplementary Fig.”
MethodJensen, C. B., Pyke, C., Rasch, M. G., Dahl, A. B., Knudsen, L. B., & Secher, A. (2018) · Endocrinology · doi:10.1210/en.2017-00812 · Cited by 145
Self-citationGLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
“GLP-1R have been identified in vascular smooth muscle cells of preglomerular arterioles in human and experimental animal kidneys [61] but cannot be easily detected by immunohistochemistry or imaging, and levels of expression may be below the sensitivity of the techniques [62].”
BackgroundJensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
Marzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121
“Historically, immunohistochemical confirmation has been hampered by the poor specificity of anti-GLP-1R antibodies (11), but better performing antibodies have enabled the distribution of GLP-1R to be more confidently ascertained in rodents, monkeys and humans (12–14).”
BackgroundGlucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas
Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119
Never waste a good crisis: confronting reproducibility in translational research
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.006 · Cited by 117
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“The limited specificity of many antibodies against mouse and human GLP-1R, combined with the challenges of detecting the receptor at low abundance, has been well documented (37, 39, 40).”
Human epicardial fat expresses glucagon-like peptide 1 and 2 receptors genes
Iacobellis, G., Camarena, V., Sant, D., & Wang, G. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-109563 · Cited by 112
“This antibody has been extensively validated to show its specificity [13, 14].”
BackgroundThe role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Ørgaard, A., & Holst, J. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4315-2 · Cited by 111
Effects of GLP-1 in the Kidney
Skov, J. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9287-7 · Cited by 106
Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104
“Detection of GLP-1R Expression in Pancreatic a-Cells Using a Specific Anti–GLP-1R Antibody Recent studies revealed that the anti–GLP-1R antibodies from major commercial sources were not specific or not sensitive enough (1,12,24).”
BackgroundFonseca, V. A., DeVries, J. H., Henry, R. R., Donsmark, M., Thomsen, H. F., & Plutzky, J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.01.009 · Cited by 100
Illuminating somatostatin analog action at neuroendocrine tumor receptors
Reubi, J. C., & Schönbrunn, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.10.001 · Cited by 98
Harasta, A. E., Power, J., von Jonquières, G., Karl, T., Drucker, D. J., Housley, G. D., Schneider, M., & Klugmann, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.47 · Cited by 97
“…Georg von Jonquieres, Ph.D.1, Tim Karl, Ph.D.2,3, Daniel J. Drucker, M.D.,Ph.D.4, Gary D. Housley, Ph.D.1, Miriam Schneider, Ph.D.5*, Matthias Klugmann, Ph.D.1*# 1Translational Neuroscience Facility & Department of Physiology, School of Medical Sciences, UNSW Australia, Sydney, NSW 2052, Australia.”
BackgroundA novel mouse model of glucagon‐like peptide‐1 receptor expression: A look at the brain
Graham, D. L., Durai, H. H., Trammell, T. S., Noble, B. L., Mortlock, D. P., Galli, A., & Stanwood, G. D. (2020) · The Journal of Comparative Neurology · doi:10.1002/cne.24905 · Cited by 94
“Thus far, attempts to develop an antibody have proven futile (Pyke & Knudsen, 2013).”
BackgroundActions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 87
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
“Moreover, fixation techniques in different cells and tissues can affect the epitopes, that also can be hidden, leading to the ambiguous identification of GLP-1R-expressing cells in humans and animal species [81].”
BackgroundThe effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Holst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 77
Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 67
“We observed that multiple anti-sera, widely used to detect GLP-1R–immunoreactive proteins, exhibit problems with sensitivity and, to a greater extent, specificity (49), findings confirmed independently by others (50).”
ResultSchönbrunn, A. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1230 · Cited by 74
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 73
Localization of Glucagon-Like Peptide-2 Receptor Expression in the Mouse
Yusta, B., Matthews, D., Koehler, J. A., Pujadas, G., Kaur, K. D., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/en.2019-00398 · Cited by 72
Egerod, K. L., Engelstoft, M. S., Lund, M. L., Grunddal, K. V., Zhao, M., Barir-Jensen, D., Nygaard, E. B., Petersen, N., Holst, J. J., & Schwartz, T. W. (2015) · Endocrinology · doi:10.1210/en.2015-1388 · Cited by 70
Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation
Hviid, A. V. R., & Sørensen, C. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00280.2019 · Cited by 69
Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
Hasan, A. A., & Hocher, B. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0005 · Cited by 68
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 67
Glucagon‐like peptide‐1 receptor is expressed in human and rodent testis
Caltabiano, R., Condorelli, D. F., Panza, S., Boitani, C., Musso, N., Ježek, D., Memeo, L., Colarossi, L., Rago, V., Mularoni, V., et al. (2020) · Andrology · doi:10.1111/andr.12871 · Cited by 63
Iacobellis, G., & Baroni, M. G. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 63
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 62
Self-citationGotfredsen, C. F., Mølck, A.-M., Thorup, I., Nyborg, N. C. B., Salanti, Z., Knudsen, L. B., & Larsen, M. O. (2014) · Diabetes · doi:10.2337/db13-1087 · Cited by 60
Self-citationNomoto, H., Miyoshi, H., Furumoto, T., Oba, K., Tsutsui, H., Miyoshi, A., Kondo, T., Tsuchida, K., Atsumi, T., Manda, N., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135854 · Cited by 52
Asmar, A., Cramon, P. K., Simonsen, L., Asmar, M., Sorensen, C. M., Madsbad, S., Moro, C., Hartmann, B., Jensen, B. L., Holst, J. J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00004 · Cited by 56
Gaspari, T. A., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 55
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Qi, L., Gröger, M., Sharma, A., Goswami, I., Chen, E., Zhong, F., Ram, A., Healy, K. E., Hsiao, E. C., Willenbring, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52258-w · Cited by 54
Moberly, S. P., Mather, K. J., Berwick, Z. C., Owen, M. K., Goodwill, A. G., Casalini, E. D., Hutchins, G. D., Green, M. A., Ng, Y., Considine, R. V., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0365-x · Cited by 54
Hou, Y., Ernst, S. A., Heidenreich, K., & Williams, J. A. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00293.2015 · Cited by 53
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 52
Grunddal, K. V., Jensen, E. P., Ørskov, C., Andersen, D. B., Windeløv, J. A., Poulsen, S. S., ROSENKILDE, M. M., Knudsen, L. B., Pyke, C., & Holst, J. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab216 · Cited by 53
Self-citationZhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 48
The endogenous preproglucagon system is not essential for gut growth homeostasis in mice
Wismann, P., Barkholt, P., Secher, T., Vrang, N., Hansen, H. B., Jeppesen, P. B., Baggio, L. L., Koehler, J. A., Drucker, D. J., Sandoval, D. A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.007 · Cited by 47
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Gastrointestinal Hormones and Their Targets
Rehfeld, J. F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-0897-4_7 · Cited by 45
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
Reagents and models for detecting endogenous GLP1R and GIPR
Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40
Roessler, J., Leistner, D. M., Landmesser, U., & Haghikia, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.018 · Cited by 40
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
Case Reports of Pre-clinical Replication Studies in Metabolism and Diabetes
von Herrath, M., Pagni, P. P., Grove, K. L., Christoffersson, G., Tang‐Christensen, M., Karlsen, A. E., & Petersen, J. S. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.004 · Cited by 39
Cardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 38
Editorial: Antibody Validation Requirements for Articles Published in Endocrinology
Gore, A. C. (2013) · Endocrinology · doi:10.1210/en.2012-2222 · Cited by 38
Katsurada, K., Nandi, S. S., Sharma, N. M., Zheng, H., Liu, X., & Patel, K. P. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2019 · Cited by 37
Yokomori, H., & Ando, W. (2020) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2019-000370 · Cited by 37
“7 We detected weak expression of GLP-1R using the earlier antibody and this MAb in normal liver.”
Jun, L. S., Showalter, A. D., Ali, N., Dai, F. F., Ma, W., Coşkun, T., FICORILLI, J. V., Wheeler, M. B., Michael, M. D., & Sloop, K. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093746 · Cited by 37
Byrd, R. A., Sorden, S. D., Ryan, T., Pienkowski, T., LaRock, R., Quander, R., Wijsman, J. A., Smith, H. W., Blackbourne, J. L., Rosol, T. J., et al. (2015) · Endocrinology · doi:10.1210/en.2014-1722 · Cited by 36
Piro, S., Mascali, L. G., Urbano, F., Filippello, A., Malaguarnera, R., Calanna, S., Rabuazzo, A. M., & Purrello, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090093 · Cited by 36
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s312527 · Cited by 36
Ast, J., Nasteska, D., Fine, N. H. F., Nieves, D. J., Kőszegi, Z., Lanoiselée, Y., Cuozzo, F., Viloria, K., Bacon, A., Luu, N. T., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35716-1 · Cited by 36
“As expected, the GLP1RA Exendin4(1-39) (Exendin4; Ex4) was able to stimulate similar magnitude insulin secretory (Fig.”
BackgroundIncretin drugs as modulators of atherosclerosis
Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
“Techniques such as in vivo autoradiography, immunohistochemistry, and in situ hybridization have identified GLP-1R in the arterial VSMCs of the kidneys in rats, mice, and monkeys, but only within a limited group of cells [18].”
BackgroundMenin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB
Muhammad, A. B., Xing, B., Liu, C., Naji, A., Ma, X., Simmons, R. A., & Hua, X. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00241.2016 · Cited by 34
Molecular chaperones and G protein-coupled receptor maturation and pharmacology
Tao, Y. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110862 · Cited by 33
Lietzau, G., Nyström, T., Östenson, C., Darsalia, V., & Patrone, C. (2016) · Oncotarget · doi:10.18632/oncotarget.6823 · Cited by 33
Structural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor
Hennen, S., Kodra, J. T., Soroka, V., Krogh, B. O., Wu, X., Kaastrup, P., Ørskov, C., Rønn, S. G., Schluckebier, G., Barbateskovic, S., et al. (2016) · Scientific Reports · doi:10.1038/srep26236 · Cited by 33
“The binding properties of mAb 3F52 to GLP-1R were characterized in a competition binding assay using 125I-GLP-1(7-37)-OH as the tracer on cell membranes expressing the human GLP-1R.”
InfluentialFortin, S. M., Chen, J. C., Petticord, M. C., Ragozzino, F. J., Peters, J. H., & Hayes, M. R. (2023) · Science Advances · doi:10.1126/sciadv.adh0980 · Cited by 32
Katsurada, K., Nandi, S. S., Zheng, H., Liu, X., Sharma, N. M., & Patel, K. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01029-0 · Cited by 32
GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?
Lovshin, J. A., & Cherney, D. Z. I. (2015) · Diabetes · doi:10.2337/db15-0366 · Cited by 32
“Recognizing that accurate localization of the GLP-1R is methodologically challenging and prone to pitfalls (19,20), extensive clarification of the presence or absence of GLP-1R expression in human endothelial cells is still required.”
BackgroundResultInfluentialNakashima, K., Kaneto, H., Shimoda, M., Kimura, T., & Kaku, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-21751-w · Cited by 32
Eid, R. A., Khalil, M. A., Alkhateeb, M. A., Eleawa, S. M., Zaki, M. S. A., El-kott, A. F., Al-Shraim, M. M., El-Sayed, F., Eldeen, M. A., Bin-Meferij, M. M., et al. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07006-9 · Cited by 32
GLP-1R activation for the treatment of stroke: Updating and future perspectives
Darsalia, V., Nathanson, D., Nyström, T., Klein, T., Sjöholm, Å., & Patrone, C. (2014) · Reviews in Endocrine & Metabolic Disorders · doi:10.1007/s11154-014-9285-9 · Cited by 26
Evidence for paracrine/autocrine regulation of GLP-1-producing cells
Krizhanovskii, C., Zhang, Q., Holst, J. J., Nyström, T., & Sjöholm, Å. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00227.2013 · Cited by 31
“However, as the specificity of the Ab used (Abcam, Cambridge, MA) was recently questioned (9, 24), further studies are necessary to confirm these data.”
BackgroundOliveira, F. C. B., Bauer, E. J., Ribeiro, C. M., Pereira, S. A., Beserra, B. T. S., Wajner, S. M., Maia, A. L., Neves, F. A. R., Coelho, M. S., & Amato, A. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.803363 · Cited by 30
Savignano, F. A., Crajoinas, R. O., Pacheco, B. P. M., Campos, L. C. G., Shimizu, M. H. M., Seguro, A. C., & Girardi, A. C. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.054 · Cited by 30
Clarke, S. J., McCormick, L. M., & Dutka, D. P. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-12 · Cited by 29
“Data with a highly specific antibody and confirmation with mRNA sequencing is also needed to clarify where the GLP-1 receptor is located in the heart [65].”
BackgroundGejl, M., Rungby, J., Brock, B., & GJEDDE, A. H. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 28
Kirk, R. K., Pyke, C., von Herrath, M. G., Hasselby, J. P., Pedersen, L., Mortensen, P. G., Knudsen, L. B., & Coppieters, K. T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12879 · Cited by 28
Self-citation
Metadata
- Authors
- Pyke, C., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2013-01-01
- Volume
- 154
- Issue
- 1
- Pages
- 4-8
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2050866589
- Cited by
- 154
- References
- 29
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 19 · 2019: 11 · 2018: 6 · 2017: 18 · 2016: 11 · 2015: 19 · 2014: 24 · 2013: 9
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, GLP-1 receptor agonists, liraglutide, exenatide, DPP-4 inhibitors, macrophages, hepatocytes, receptor localization, type 2 diabetes, atherosclerosis, hepatic steatosis, G protein-coupled receptors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.